CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) ROCE % : 19.82% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is CSPC Pharmaceutical Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CSPC Pharmaceutical Group's annualized ROCE % for the quarter that ended in Dec. 2023 was 19.82%.

CSPC Pharmaceutical Group ROCE % Historical Data

The historical data trend for CSPC Pharmaceutical Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group ROCE % Chart

CSPC Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

25.63

30.14

27.06

24.18

21.28

CSPC Pharmaceutical Group Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															24.32	22.02	22.01	21.91	19.82

CSPC Pharmaceutical Group ROCE % Calculation

CSPC Pharmaceutical Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1038.524	/	( ( (5991.333 - 1284.909)	+	(6481.915 - 1426.091) )	/ 2 )
	=	1038.524	/	( (4706.424	+	5055.824)	/ 2 )
	=	1038.524	/	4881.124
	=	21.28 %

CSPC Pharmaceutical Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1002.008	/	( ( (0 - 0)	+	(6481.915 - 1426.091) )	/ 1 )
	=	1002.008	/	( ( 0	+	5055.824 )	/ 1 )
	=	1002.008	/	5055.824
	=	19.82 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

CSPC Pharmaceutical Group (OTCPK:CHJTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CSPC Pharmaceutical Group ROCE % Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (OTCPK:CHJTF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CSPCY:USA 01093:Hong Kong CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) Headlines

From GuruFocus

Value Partners Classic Fund Comments on CSPC Pharmaceutical

By Vera Yuan Vera Yuan • 07-29-2014